Legislators on Capitol Hill are moving forward this month with bills that address patent issues pertaining to biosimilars.
Legislators on Capitol Hill are moving forward this month with bills that address patent issues pertaining to biosimilars.
Earlier this month, Representatives Hakeem Jeffries, D-New York, and Doug Collins, R-Georgia, introduced the bipartisan Terminating the Extension of Rights Misappropriated (TERM) Act of 2019. The bills would limit patent evergreening, a tactic whereby drug companies make minor changes to a drug and file for a new patent on those small changes in order to extend their exclusivity and, in turn, charge more costly prices.
Under existing patent law, generic drug manufacturers must prove why a new patent should not be granted on an existing medication. The TERM Act shifts that burden of proof to pharmaceutical companies, who would have to demonstrate “distinct inventions” in order qualify a changed drug for a new patent.
In addition, the bill directs the director of the United States Patent and Trademark Office to send a report to the Judiciary committee in the House of Representatives a year after the bill becomes law. The report would contain a review and recommendations regarding best examination practices, guidance, and procedures to avoid patent evergreening.
“The bipartisan TERM Act will curb patent abuses in order to expedite the entrance of lower cost generic drugs to market,” Jeffries said in a statement.
“Competition in the pharmaceutical market decreases costs and increases options for patients. Pharmaceutical companies are great innovators that create life-saving cures and treatments for families everywhere. Unfortunately, some manufacturers simply file additional patents in order to delay generic drugs from coming to market,” Collins added.
The bill is co-sponsored by Representatives Debbie Mucarsel-Powell, D-Florida, and Ben Cline, R-Virginia.
On the Senate side, Lamar Alexander, R-Tennessee, and Patty Murray, D-Washington, recently introduced S 1895, the Lower Health Care Costs Act of 2019, which includes biosimilars’ role in reducing the prices of prescription drugs. Alexander is chairman and Murray is ranking member of the Senate Committee on Health, Education, Labor, and Pensions, which will vote on the bill on June 26.
One part of the legislation would require updates to the FDA’s Purple Book, which provides stakeholders with information on biologics. The legislation would codify the Purple Book as a single, searchable list of information that would include, among other information, materials related to patents on biologics.
Alexander’s committee has held 5 hearings on ways to reduce healthcare costs and 4 hearings on the cost of prescription drugs. The bill is made up of nearly 3 dozen discrete provisions from at least 16 Republican and 14 Democrat lawmakers.
Besides addressing certain aspects of prescription drug prices, the bill also seeks to end surprise medical bills, increase transparency in healthcare, improve public health, and improve the exchange of health information.
Another recently introduced Senate bill would give the Federal Trade Commission the authority to bring antitrust suits against pharmaceutical companies for blocking competition through the use of the patent system.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.